Help Vanessa get life-saving treatment
Help Vanessa get life-saving treatment for atypical hemolytic uremic syndrome (aHUS)
AucklandOn January 24, Vanessa, a senior lecturer at The University of Auckland and NZ citizen, was admitted to Auckland City Hospital and later diagnosed with atypical hemolytic uremic syndrome (aHUS), an ultra-rare, life-threatening disease for which the only treatment proven to be effective is eculizumab (marketed under the brand name Soliris). Eculizumab has been approved in New Zealand but it's not publicly funded.
Eculizumab treatment costs about 100 000 NZD for the first month and then about 60 000 NZD each subsequent month.
Vanessa has savings to cover just the first month of the treatment. Her intention is to get treated in New Zealand for as long as it's necessary for her to be healthy enough to travel to Spain to continue her treatment.
This fundraiser aims to cover 3 months of treatment, at 60 000 NZD/month.
Marina Sanchez's involvement (page creator)
Long-time, dear friend
Use of funds
All the money received through this campaign will go exclusively to support Vanessa's hospital and treatment expenses for as long as it's needed for her to be strong enough to fly to Spain and continue her treatment there.
Latest update
5th dose received / 5a dosis recibida 5 March 2021
This week's update is short and sweet. Vanessa received on Thursday her 5th dose of eculizumab. She is surely and steadily on her path to recovery, thanks to each and everyone of you.
Once again: thank you for being there for her.
El mensaje de esta semana es breve, pero relevante. Vane ha recibido hoy la quinta dosis de eculizumab, y sigue avanzando de forma segura y firme en el camino hacia la recuperación, gracias a todos y cada uno de vosotros.
Gracias, de nuevo, por estar a su lado.
Latest donations
Who's involved?
Want to get in touch with Marina Sanchez?
7 questions have been asked already. Check them out and ask yours here.Any concerns?
Report this pageThis page was created on 3 Feb 2021 and closed on 24 Feb 2021.